NCT05940480

Brief Summary

Chronic obstructive pulmonary disease (COPD) is a common, preventable and treatable disease. The aim of prospective randomized study is to evaluate the effects of TCM Daoyin training on Individuals at-risk for COPD.

Trial Health

75
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
60

participants targeted

Target at P50-P75 for not_applicable chronic-obstructive-pulmonary-disease

Timeline
21mo left

Started Jan 2023

Longer than P75 for not_applicable chronic-obstructive-pulmonary-disease

Geographic Reach
1 country

2 active sites

Status
active not recruiting

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Progress66%
Jan 2023Dec 2027

Study Start

First participant enrolled

January 3, 2023

Completed
6 months until next milestone

First Submitted

Initial submission to the registry

July 4, 2023

Completed
7 days until next milestone

First Posted

Study publicly available on registry

July 11, 2023

Completed
4 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

June 30, 2027

Expected
6 months until next milestone

Study Completion

Last participant's last visit for all outcomes

December 31, 2027

Last Updated

April 3, 2025

Status Verified

March 1, 2025

Enrollment Period

4.5 years

First QC Date

July 4, 2023

Last Update Submit

March 29, 2025

Conditions

Keywords

TCM Daoyinat-risk for COPDearly COPDchronic obstructive pulmonary disease

Outcome Measures

Primary Outcomes (1)

  • Lung function

    Participants' lung function (FVC、FVC%、FEV1、FEV1%、FEV1/FVC) will be tested to identify air flow condition in both group.

    Change from Baseline lung function at 16 weeks

Secondary Outcomes (6)

  • 6-min walk distance(6MWD)

    Change from Baseline 6MWD at 16 weeks

  • Immune function

    Change from Baseline immune function at 16 weeks

  • Depression, Anxiety and Stress Scale-21 item (DASS-21)

    Change from Baseline DASS-21 at 16 weeks

  • St. George's Respiratory Questionnaire (SGRQ)

    Change from Baseline SGRQ at 16 weeks

  • Adverse effects

    8 weeks

  • +1 more secondary outcomes

Study Arms (2)

TCM Daoyin intervention group

EXPERIMENTAL

Participants randomized to TCM Daoyin intervention group receive health education plus a TCM Daoyin training program. The TCM Daoyin training program was a 16-week, instructor-led group training program.

Behavioral: TCM DaoyinBehavioral: Health education

Health education control group

ACTIVE COMPARATOR

Participants randomized to the health education control group only receive health education and no additional training program.

Behavioral: Health education

Interventions

TCM DaoyinBEHAVIORAL

The TCM Daoyin training program consisted of two 90-min training classes and at least five 30-min at-home practice sessions per week for 16-weeks. All sessions included 10 min of warmup and 10 min of cooldown.

Also known as: Qigong
TCM Daoyin intervention group

Health education is provided by doctor and nurse, including work, rest, diet and other basic programs.

Health education control groupTCM Daoyin intervention group

Eligibility Criteria

Age40 Years - 75 Years
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Subject at-risk for COPD (Chronic obstructive pulmonary disease screening questionnaire (COPD-SQ) score≥16; and pre-bronchodilator FEV1/FVC ≥ 0.70, or pre-bronchodilator FEV1/FVC\<0.70 but post-bronchodilator FEV1/FVC ≥ 0.70).
  • Aged 40 to 75, male or female.
  • Subject has a clear mind and the ability to lead an independent life.
  • Subject agrees to perform a blood-test.
  • Subject agrees to participate in this study and sign to the informed consent.

You may not qualify if:

  • Subject with acute exacerbation of COPD.
  • Subject with respiratory infectious disease (e.g., tuberculosis, influenza, etc.) within 1 month.
  • Subject with serious current unstable physical illness and mental illness.
  • Subject with definite clinical diagnosis of Alzheimer's disease, or severe cognitive impairment.
  • Subject is pregnant or lactating women.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (2)

Shanghai Qigong Research Institute

Shanghai, Shanghai Municipality, 021, China

Location

Changzheng Community Health Service Center of Putuo District, Shanghai

Shanghai, Shanghai Municipality, 200333, China

Location

MeSH Terms

Conditions

Pulmonary Disease, Chronic ObstructiveLung Diseases, Obstructive

Interventions

Qigong

Condition Hierarchy (Ancestors)

Lung DiseasesRespiratory Tract DiseasesChronic DiseaseDisease AttributesPathologic ProcessesPathological Conditions, Signs and Symptoms

Intervention Hierarchy (Ancestors)

Breathing ExercisesMind-Body TherapiesComplementary TherapiesTherapeuticsExercise Movement TechniquesPhysical Therapy Modalities

Study Officials

  • Xiaoting Zhao

    Shanghai Qigong Research Institute

    STUDY CHAIR
  • Jie Li, Doctor

    Shanghai University of Traditional Chinese Medicine

    STUDY DIRECTOR
  • Ying Lu, Master

    Shanghai Qigong Research Institute

    PRINCIPAL INVESTIGATOR

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
SINGLE
Who Masked
OUTCOMES ASSESSOR
Masking Details
The outcome assessors were blinded to the group allocation of the participants.
Purpose
TREATMENT
Intervention Model
PARALLEL
Model Details: This study is a 16-week, randomized controlled trial. Individuals at-risk for COPD are randomized to either TCM Daoyin intervention group or health education control group.
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
assistant researcher

Study Record Dates

First Submitted

July 4, 2023

First Posted

July 11, 2023

Study Start

January 3, 2023

Primary Completion (Estimated)

June 30, 2027

Study Completion (Estimated)

December 31, 2027

Last Updated

April 3, 2025

Record last verified: 2025-03

Data Sharing

IPD Sharing
Will not share

Locations